Pharmacokinetic Evaluations of Ixekizumab Following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients With Moderate-to-Severe Plaque Psoriasis

Trial Profile

Pharmacokinetic Evaluations of Ixekizumab Following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients With Moderate-to-Severe Plaque Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Ixekizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacokinetics; Registrational
  • Acronyms UNCOVER-A
  • Sponsors Eli Lilly
  • Most Recent Events

    • 24 Dec 2016 Results of an integrated analysis of UNCOVER-1, UNCOVER-2, UNCOVER-3, UNCOVER-A, UNCOVER-J and two other phase 1 and phase 2 studies published in the Journal of the American Academy of Dermatology.
    • 08 Mar 2016 Results of sub-group analysis (n=102) presented at the 74th Annual Meeting of the American Academy of Dermatology.
    • 08 Mar 2016 Results presented at the 74th Annual Meeting of the American Academy of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top